[Treatment of macroprolactinoma with cabergoline during pregnancy].
OBJECTIVE
Management of macroprolactinomas in women who plan to get pregnant is controversial and when this happen there is a risk of pituitary enlargement, if this happens bromocriptine has a safe profile to be used during pregnancy, but if it is not tolerated cabergoline is a good alternative.


METHODS
We describe two patients with macroprolactinomas who intended to get pregnant. One of them had been previously treated surgically and the second one was treated with bromocriptine and got pregnant before the tomographic studies were checked. Both patients developed during pregnancy symptoms of macroprolactinoma enlargement and were initially treated with bromocriptine but this was not tolerated and were switched to cabergoline. Both pregnancies ended with a normal full term newborn.


CONCLUSIONS
Pregnant women with symptoms of pituitary enlargement must be treated with bromocriptine, but if it is not tolerated cabergoline is a good choice.
Forsbach-Sánchez
Gerardo
G
Hospital de Ginecoobstetricia Dr. Ignacio Morones, Unidad Médica de Alta Especialidad 23, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León. gbforsbach@yahoo.com
Tamez-Pérez
Héctor E
HE
Hernández-Herrera
Ricardo
R
Bafidis-Lechuga
Bertha
B
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D015175:Prolactinoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004873:Ergolines; D000077465:Cabergoline